Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement
Open Access
- 1 March 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 9 (2), 98-103
- https://doi.org/10.1097/00054725-200303000-00003
Abstract
Perianal fistulas occur in approximately 30% of patients with Crohn's disease (CD). Infliximab, a chimeric monoclonal antibody targeting human tumor necrosis factor alpha (TNF(), is approved for the treatment of fistulizing CD. Although the initial response to infliximab is dramatic, the median duration of fistula closure is approximately 3 months, and repeated infusions are often required. An exam under anesthesia (EUA) by a surgeon allows for complete inspection of the fistula as well as incision and drainage of an abscess and placement of a seton. Our aim was to compare the rate of perianal fistula healing, relapse rate, and time to relapse in patients with fistulizing CD treated with infliximab alone or as an adjunct to surgical EUA with seton placement. Thirty-two consecutive patients with perianal fistulizing CD who completed at least 3 infusions with infliximab (5 mg/kg at 0, 2, 6 weeks) between October 1999 and October 2001 were analyzed. All patients had at least 3 months of follow-up after the third dose of infliximab. Response was defined as complete closure and cessation of drainage from the fistula. Patients with CD and perianal fistulas who had an EUA prior to infliximab infusions had a better initial response (100% vs. 82.6%, p = 0.014), lower recurrence rate (44% vs. 79%, p = 0.001), and longer time to recurrence (13.5 months vs. 3.6 months, p = 0.0001) compared with patients receiving infliximab alone. In conclusion, patients with fistulizing CD treated with infliximab are more likely to maintain fistula closure if treatment is preceded by EUA and seton placement.Keywords
This publication has 11 references indexed in Scilit:
- Diagnosis and Treatment of Perianal Fistulas in Crohn DiseaseAnnals of Internal Medicine, 2001
- MRI imaging of the effects of infliximab in perianal fistulizing Crohn's diseaseGastroenterology, 2001
- Treatment of fistulizing Crohn's diseaseGastroenterology, 2000
- Surgical treatment of anorectal complications in Crohn's diseaseSurgery, 2000
- Management of Perianal Crohn's DiseaseCanadian Journal of Gastroenterology, 2000
- Review article: the efficacy of infliximab in Crohn’s disease — healing of fistulaeAlimentary Pharmacology & Therapeutics, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- Medical and Surgical Management of Perianal Crohnʼs DiseaseInflammatory Bowel Diseases, 1996
- Twenty-year review of the surgical management of perianal Crohn's diseaseDiseases of the Colon & Rectum, 1995
- National Cooperative Crohn's Disease Study: Extraintestinal manifestations and perianal complicationsGastroenterology, 1979